Study to assess the efficacy of sorafenib in resected metastatic renal cell cancer.
Active, not recruiting
- Conditions
- Advanced metastatic resected renal cell carcinomaMedDRA version: 15.0Level: SOCClassification code 10038359Term: Renal and urinary disordersSystem Organ Class: 10038359 - Renal and urinary disordersTherapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2012-000708-14-IT
- Lead Sponsor
- ISTITUTO NAZIONALE PER LA CURA TUMORI
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Hystological diagnosis of RCC Metastases radically resected Clear cell hystotypes
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 132
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Metastases non radically resected Age less than 18 years Non clear cells histotypes
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method